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TRANSFER RNA PROCESSING 
 
 
The major steps required for maturation of tRNAs involves the processing of 5´- and 3´-
extensions, followed by 3´-CCA addition and post-transcriptional modifications.  
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ABSTRACT 
The mammalian mitochondria are subcellular organelles, generating energy in the cell by the 
synthesis of adenosine triphosphate (ATP) via oxidative phosphorylation (OXPHOS). The 
maintenance of proper mitochondrial (mt) structure and function requires more than 1000 
proteins generated from the nuclear DNA (nDNA) expression and 13 protein subunits 
generated from the mitochondrial DNA (mtDNA) expression. The transcription of the two 
strands of mtDNA generates two long polycistronic precursor ribonucleic acid (pre-RNA) 
molecules harboring the precursor messenger RNAs (pre-mRNAs), precursor ribosomal 
RNAs (pre-rRNAs) and precursor transfer RNAs (pre-tRNAs) at a stretch. The processing of 
pre-tRNAs punctuating the pre-rRNAs and most of the pre-mRNAs causes the release of 
each of the RNA species that undergo their own respective maturation pathways to attain the 
functional state. This thesis explores the molecular mechanism of pre-tRNA processing in 
human mitochondria, critical for several downstream processes such as mitoribosome 
biogenesis and the maturation of mt-mRNAs and mt-tRNAs.  
The first step of pre-tRNA processing is performed by the human mitochondrial ribonuclease 
P (mt-RNase P) composed of three protein subunits: MRPP1, MRPP2 and MRPP3 that 
excises the tRNA at the 5´-end. In Paper I, the high-resolution crystal structure of the 
MRPP3 protein is described. We observed that the MRPP3 protein is unable to perform 5´-
tRNA cleavage on its own because of its distorted active site. Unlike its structural 
homologue: protein-only RNase P 1 (PRORP1) found in the plant mitochondria and 
chloroplasts, MRPP3 requires a subcomplex of MRPP1 and MRPP2 (MRPP1/2) and pre-
tRNA substrate to undergo conformational changes in the presence of metal ions to achieve 
an active state. In Paper II, previously unknown central role of MRPP1/2 complex as a 
maturation platform for mt-tRNAs is reported. We show that the MRPP1/2 complex is not 
just an essential component of human mt-RNase P, but also significantly enhances the 3´-
processing by the ELAC2 protein in 17 out of 22 5´-processed mt-tRNAs. Moreover, the 
CCA addition to the 3´-processed tRNAs was shown to be possible while the tRNA remained 
bound to the MRPP1/2 complex. Thus, the MRPP1/2 sub-complex hosts the pre-tRNA 
substrate through three major steps of the processing activities instead of just one as thought 
previously.  
The human mt-tRNA genes in the mtDNA are locations for several disease-causing 
mutations causing mt encephalomyopathies. In Paper III, the role of disease-causing 
tRNA(Lys) acceptor stem mutations is evaluated in terms of its effects on mt-RNase P 
activity. An overall impairment of RNase P processing was observed in tRNA acceptor stem 
mutants in relation to the wild type tRNA. The MRPP1/2 complex can bypass a single point 
mutation in the acceptor stem of substrate pre-tRNA and form a stable complex in vitro. 
However, the nuclease activity by MRPP3 is strongly affected. We speculate that either the 
MRPP3 protein is unable to form a complex with MRPP1/2-pre-tRNA or the re-organization 
of its active site upon binding to MRPP1/2-pre-tRNA is affected as a consequence of the 
acceptor stem mutation.  
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1 INTRODUCTION 
 
The work presented in this thesis provides a detailed description of the human mt-tRNA 
processing and maturation at a molecular level. In the introductory chapter 1, the mammalian 
mt system and its genome organization is described along with a brief overview of human 
mt-tRNAs. In chapter 2, the molecular players involved in the processing of mt-tRNAs are 
described in detail. The mt-tRNA mutations and its implications in pathology of medically 
relevant human diseases are covered in chapter 3. The strategy employed to systematically 
form and analyze protein-protein and protein-tRNA complexes are provided in chapter 4. 
This is followed by a summary of papers and a discussion of the future perspectives in 
chapter 5 and 6 respectively.  
 
1.1 Mitochondria 
The mammalian mitochondrion is a vital organelle in the cell performing a wide variety of 
functions including the synthesis of ATP via the transfer of electrons through a complex 
mechanism called OXPHOS. It is made up of two compartments called the outer membrane 
and the inner membrane (Figure 1), the latter forming structures called cristae [1]. The folded 
crista harbors assemblies of four respiratory chain complexes (complex I – IV) and one ATP 
synthase (complex V) that function as a bio-energetic system for ATP production [2, 3].  
 
 
 
Figure 1: The cross-section of mitochondria shows inner membrane, outer membrane and mt matrix. The 
intermembrane space separates the two compartments.  
Outer membrane
Inner membrane
Mitochondrial matrix
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Apart from generating the energy currency of the cell, the mitochondrion has a significant 
control over cellular homeostasis as a regulator of the level of amino acids, critical 
metabolites and several other cofactors. It serves as a source of nicotinamide adenine 
dinucleotide (NADH) for the cell and is also critical for metabolism of metals, oxidation of 
fatty acids, apoptosis and signal transduction [4-7]. It has a very high medical relevance as it 
is implicated in aging, diabetes, obesity, immunity, neurodegenerative disorders and a wide 
spectrum of human mt diseases [2, 8-13]. 
 
1.2 Organization of the mitochondrial genome 
The mammalian mitochondrion harbors multiple copies of mtDNA organized as compact 
nucleoprotein structures called nucleoids in the mt matrix [14]. The mtDNA is a circular, 
compact, double-stranded molecule of around 16.5 kb that encodes 13 essential proteins, 22 
tRNAs (Figure 2) and 2 rRNAs required for mitoribosome biogenesis and OXPHOS [15-17]. 
The remaining proteins needed for OXPHOS requires nuclear gene expression, the products 
of which are targeted to mitochondria. A total of around 1100 nuclear-encoded proteins are 
required for multiple purposes within mitochondria including OXPHOS, pre-RNA 
processing, mtDNA expression and maintenance [18, 19].  
The mammalian mtDNA is composed of two strands, a heavy (H) strand and a light (L) 
strand, named historically due to their differing densities [20]. This difference is due to the 
variations in the nucleotide content between the two strands. The H strand is rich in its 
guanine content relative to the complementary L strand [21]. Each of the two strands harbors 
a main promoter called the heavy strand promoter (HSP) and the light strand promoter (LSP) 
at a non-coding region called displacement loop (D-loop). Thus, the D-loop serves as the 
transcription initiation sites. The H strand harbors 14 mt-tRNA genes (Table 1), 2 rRNA 
genes and all the mRNA elements (Table 2) except the gene coding for NADH 
dehydrogenase subunit 6 (ND6). The L strand harbors ND6 gene and the remaining 8 mt-
tRNA genes (Table 1).  
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Figure 2: Color-coded schematic representation of mammalian mtDNA showing H and L strands in dark and 
light blue respectively. The mRNA elements, tRNA elements and rRNA elements are shown in orange, green 
and red, respectively. The tRNA genes are indicated using standard one-letter nomenclature for amino acids. The 
abbreviations of tRNAs and mRNAs are provided in tables 1 and 2 respectively.  
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Name Abbreviation Location in 
mtDNA 
Strand D      loop 
(bases) 
Variable loop 
(bases) 
TΨC loop 
(bases) 
Mitochondrial tRNA Phenylalanine mt-tRNAPhe 
(F/Phe) 
577-647 Heavy 9 4 5 
Mitochondrial tRNA Valine mt-tRNAVal   
(V/Val) 
1602-1670 Heavy 6 4 6 
Mitochondrial tRNA Leucine(UUR) mt-tRNALeu(UUR) 
(L2/Leu2) 
3230-3304 Heavy 10 5 7 
Mitochondrial tRNA Isoleucine mt-tRNAIle       
(I/Ile) 
4263-4331 Heavy 4 5 7 
Mitochondrial tRNA Methionine mt-tRNAMet 
(M/Met) 
4402-4469 Heavy 5 4 6 
Mitochondrial tRNA Tryptophane mt-tRNATrp   
(W/Trp) 
5512-5579 Heavy 7 4 4 
Mitochondrial tRNA Aspartate mt-tRNAAsp 
(D/Asp) 
7518-7585 Heavy 5 4 6 
Mitochondrial tRNA Lysine mt-tRNALys  
(K/Lys) 
8295-8364 Heavy 3 5 9 
Mitochondrial tRNA Glycine mt-tRNAGly  
(G/Gly) 
9991-10058 Heavy 5 4 6 
Mitochondrial tRNA Arginine mt-tRNAArg  
(R/Arg) 
10405-10469 Heavy 5 4 3 
Mitochondrial tRNA Histidine mt-tRNAHis   
(H/His) 
12138-12206 Heavy 5 4 7 
Mitochondrial tRNA Serine(AGY) mt-tRNASer(AGY) 
(S1/Ser1) 
12207-12265 Heavy 2 4 8 
Mitochondrial tRNA Leucine(CUN) mt-tRNALeu(CUN) 
(L1/Leu1) 
12266-12336 Heavy 7 4 7 
Mitochondrial tRNA Threonine mt-tRNAThr   
(T/Thr) 
15888-15953 Heavy 6 4 3 
Mitochondrial tRNA Proline mt-tRNAPro    
(P/Pro) 
15956-16023 Light 6 4 5 
Mitochondrial tRNA Glutamate mt-tRNAGlu    
(E/Glu) 
14674-14742 Light 5 4 7 
Mitochondrial tRNA Serine(UCN) mt-tRNASer(UCN) 
(S2/Ser2) 
7446-7514 Light 5 4 7 
Mitochondrial tRNA Tyrosine mt-tRNATyr   
(Y/Tyr) 
5826-5891 Light 4 4 5 
Mitochondrial tRNA Cysteine mt-tRNACys  
(C/Cys) 
5761-5826 Light 3 4 6 
Mitochondrial tRNA Asparagine mt-tRNAAsn 
(N/Asn) 
5657-5729 Light 8 5 7 
Mitochondrial tRNA Alanine mt-tRNAAla  
(A/Ala) 
5587-5655 Light 5 4 7 
Mitochondrial tRNA Glutamine mt-tRNAGln  
(Q/Gln) 
4329-4400 Light 8 4 7 
 
Table 1: A list of all 22 mt-tRNAs in human mitochondria arranged based on their location in the mt genome. 
The numbers of bases constituting the D loop, variable loop and TΨC loop are given for each mt-tRNA. 
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Abbreviation Full name Location in mtDNA Strand Respiratory chain 
component 
Cyt b Cytochrome b 14747-15887 Heavy Complex III 
ND6 NADH dehydrogenase subunit 6 14149-14673 Light Complex I 
ND5 NADH dehydrogenase subunit 5 12337-14148 Heavy Complex I 
ND4 NADH dehydrogenase subunit 4 10760-12137 Heavy Complex I 
ND4L NADH dehydrogenase subunit 4L 10470-10766 Heavy Complex I 
ND3 NADH dehydrogenase subunit 3 10059-10404 Heavy Complex I 
COIII Cytochrome C oxidase subunit III 9207-9990 Heavy Complex IV 
ATP6 ATP synthase 6 8227-9207 Heavy Complex V 
ATP8 ATP synthase 8 8366-8572 Heavy Complex V 
COII Cytochrome C oxidase subunit II 7586-8294 Heavy Complex IV 
COI Cytochrome C oxidase subunit I 5904-7444 Heavy Complex IV 
ND2 NADH dehydrogenase subunit 2 4470-5511 Heavy Complex I 
ND1 NADH dehydrogenase subunit 1 3307-4262 Heavy Complex I 
 
Table 2: A list of the 13 mt-mRNAs encoded in human mtDNA, their respective locations in mtDNA and the 
assemblies of their gene products into various respiratory chain complexes [15]. The data was compiled from 
Online Mendelian Inheritance in Man (OMIM) database [22]. The color code represents the clusters of genes 
that form different complexes of respiratory chain.  
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1.3 Crosstalk between mitochondria and nucleus  
The mitochondrion and the nucleus are involved in cellular crosstalk as a means of regulation 
of mt function and possibly a complementary retrograde signaling mechanism to control 
nuclear gene expression [23]. The assembly of respiratory complexes involved in OXPHOS 
requires both mtDNA and nuclear gene expression, wherein, the products of the latter such as 
mitochondrial DNA-directed RNA polymerase (POLRMT), mitochondrial transcription 
factor A (TFAM) and mitochondrial transcription factor B2 (TFB2M) crucial for mtDNA 
transcription are imported into the mitochondria via protein import systems [21, 24, 25] 
(Figure 3).  
 
 
 
Figure 3: An illustration providing an overview of the path to generate ATP that entails both the mitochondrion 
and the nucleus. Several proteins produced in the cytosol enter the mitochondrion and perform mtDNA 
replication, transcription and processing of transcripts towards maturation of all RNA species, ultimately 
contributing to a proper mt function.  
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The nuclear encoded POLRMT is a single-subunit RNA polymerase that transcribes the H 
and L strands in the presence of TFAM and TFB2M to generate two long polycistronic 
transcripts that are substrates for extensive processing by mt-processing machinery [21, 26-
29]. The precursor RNA processing occurs co-transcriptionally and is initiated in structures 
called as mitochondrial RNA granules (MRGs) [30-32] located near nucleoids. Except the 
mRNA clusters ATP6-COIII and ND5-Cytb, all elements are flanked by atleast one tRNA 
gene. According to the tRNA punctuation model [17], the RNA processing is initiated on 
these tRNA sequences interspersed in between non-coding rRNA and most of the coding 
mRNA elements. The mt-RNase P and the mitochondrial ribonuclease Z (mt-RNase Z) are 
responsible for 5´- and 3´-processing activities that release individual mRNAs, rRNAs and 
tRNAs, each of which undergo their own maturation pathways [26]. The mature mt-rRNA 
and mt-tRNAVal species participate in mitoribosome biogenesis and translate mt-mRNA 
elements to generate components of mt respiratory system [33, 34]. 
 
1.4 Mitochondrial transfer RNAs 
The tRNAs are a vital class of biomolecules participating in the ribosomal translation of 
mRNAs, delivering codon-specific amino acids aiding protein synthesis [35]. The secondary 
structure of tRNAs form a cloverleaf and has several subdomains: an acceptor stem, D arm, 
anticodon stemloop, TΨC arm and a variable loop (Figure 4). Noteworthy, a few alternate 
tRNA secondary structural folds exist [35, 36]. These tRNAs with varying sequence and 
structural features undergo tertiary folding to a 3-dimensional L-shaped structure (Figure 5) 
before aminoacylation [35].  
The early discovery of structure of tRNAs from the mitochondria of parasitic nematode worm 
Ascaris suum was considered ‘bizzare’ as it completely lacked the TΨC arm and variable 
loop [37]. The sequence and structural features of human mt-tRNAs also widely varies, 
differing in the lengths of different subdomains (Table 1). The mitochondria of many 
eukaryotic organisms such as humans harbor a complete set of tRNAs within its genome 
[15].  
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Figure 4: Color-coded cloverleaf representation of human mt-tRNAs harboring a 7-base pair acceptor stem, 4-
base pair D stem, 5-base pair anticodon stem and 5-bp TΨC stem, all stabilized by WC base pairing. The mt-
tRNASer(AGY) lacks the D stem. In 22 mt-tRNAs, the D loop varies between 2 to 10 bases, variable loop varies 
between 4 and 5 bases and the T loop varies between 3 to 9 bases.  
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Figure 5: 3D color-coded representation of tertiary structure of mature tRNAs using X-ray structure of yeast 
tRNAPhe [38] as reference. Inbox: Respective 2D color-coded cloverleaf-representation.  
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2 MITOCHONDRIAL TRANSFER RNA BIOGENESIS 
 
The human mt-tRNA biogenesis is a systematic process involving several processing 
enzymes. The purpose of these mt-tRNAs is to aid the translation of 13 polypeptides encoded 
in mtDNA by delivering codon-specific amino acids to the mitoribosome. A thorough 
understanding of these mechanisms is crucial to address human mitochondrial diseases. In 
this chapter, the enzymes participating in these processes are discussed.   
 
2.1 Human mitochondrial RNase P 
2.1.1 Background 
RNase P is an endonuclease performing the processing of 5´-pre-tRNAs across the three 
kingdoms of life [39-41] and was first discovered in bacteria [42]. Although the function of 
this enzyme is universally conserved, it displays stark structural diversity [43].  
The bacterial RNase P is made up of a catalytic RNA component and a compact protein 
involved in the recognition of pre-tRNA 5´-leader sequences [44-46]. In higher organisms, 
the protein moeity constituting the RNA-based RNase P widely varies (Figure 6) with the 
archaeal RNase P composed of 4-5 proteins and eukaryotic nuclear RNase P composed of 
upto 10 proteins [40, 47-51]. While the bacterial RNase P RNA is active on its own in vitro 
[45], the RNA subunits of few archaeal and eukaryal RNase P display very low activity on its 
own [52, 53] highlighting the role of increased protein content in the latter cases. Thus, the 
evolution of RNase P supports the so-called ‘RNA world hypothesis’ that suggests a common 
primordial, prebiotic RNA to have evolved to function with proteins [43, 54, 55]. The 
existence of protein-only RNase P’s (PRORPs) were long speculated [56] and supported by 
few reports  [57-59], yet, their existence was fully consolidated much later with the discovery 
of PRORP in human mitochondria [60].  
The three protein subunits: MRPP1, MRPP2 and MRPP3 constitute the human mt-RNase P 
[60, 61]. Unlike the RNase P’s found in nature, the human mt-RNase P is not a 
ribonucleoprotein complex and is composed of only protein subunits (Figure 7) completely 
lacking any RNA subunit [60, 61]. The plant mt-RNase P also belongs to PRORP class of 
enzymes, wherein only a single protein subunit PRORP1 performs the 5´-pre-tRNA cleavage 
[62, 63].  
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Figure 6: Structural diversity of RNase P across different kingdoms of life. The panel in the left provides three 
examples of RNA-based RNase P and the panel in the right provides two examples of PRORPs. 
 
2.1.2 MRPP1 
MRPP1, also called tRNA methyltransferase 10 homolog C (TRMT10C) is a nuclear-
encoded RNA-methyltransferase (MTase) targeted to mitochondria that uses S-adenosyl 
methionine (SAM) as a co-factor to perform N1-methylation of purines at position 9 of 
human mt-tRNAs, prevalently (19/22 mt-tRNAs) occupied by either a G or A [64-66]. The 
methylation of mt-tRNAs allows them to achieve proper folding [67, 68], yet is not a pre-
requisite for 5´-tRNA cleavage by mt-RNase P [64]. The proper functioning of MRPP1 
protein is heavily dependent upon the expression of a multifunctional protein called MRPP2, 
the knockdown of which was shown to strongly influence the steady-state levels of MRPP1 
[69]. Noteworthy, the steady-state levels of MRPP2 remained unaffected by knockdown of 
MRPP1 [69]. Thus, MRPP2 can also be attributed the methyltransferase function (Figure 7).  
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MRPP1 belongs to the Trm10 family of MTases classified under class IV SpoU-TrmD 
(SPOUT) superfamily, the characteristic feature of which is the formation of tight 
homodimers and the presence of a trefoil-knot structure in its SAM-binding catalytic domain 
[70-74]. Several isoforms of Trm10 homologs are present in humans, wherein MRPP1 
evolved separately [75] and is suggested to differ from the other Trm10 isoforms such as 
TrmT10A and TrmT10B with regard to mechanism of pre-tRNA substrate recognition. The 
MRPP1 and MRPP2 proteins form a strong complex [64, 65] and is a subcomplex of mt-
RNase P [60]. Thus, the tRNA binding, substrate specificity and methylation function resides 
in MRPP1 [71], while the precise mechanism by which MRPP2 promotes MRPP1 remains to 
be elucidated.  
 
2.1.3 MRPP2 
The nuclear encoded MRPP2 protein is localized to mitochondria [76] and acts on a wide 
variety of substrates to perform multiple functions within the cell. They include isoleucine 
degradation, metabolism of sex hormones, β-oxidation of fatty acids, metabolism of 
neuroactive steroids among others [77-83]. Owing to its multifunctional role in many cellular 
pathways, it has been assigned multiple names such as short-chain dehydrogenase/reductase 
5C1 (SDR5C1), 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), 2-methyl-3-
hydroxybutyryl-CoA dehydrogenase (MHBD) and amyloid β-peptide-binding alcohol 
dehydrogenase (ABAD) [76, 84, 85]. It is a NADH-dependent protein required for the 
stabilization of MRPP1 and has an oligomeric state of a tetramer [69, 86]. Its exact role as a 
component of human mt-RNase P is so far unknown, but has been speculated to contribute to 
the substrate tRNA-binding in the MRPP1/2 complex via its Rossmann fold [60, 87, 88].  
 
2.1.4 MRPP3  
The KIAA0391 gene product coding for a large uncharacterized protein [89] was discovered 
to be the third component of human mt-RNase P (named as MRPP3) that along with MRPP1 
and MRPP2 is essential for 5´-tRNA processing [60]. It is a nuclear-encoded mt protein [65] 
and is one of the few pentatricopeptide repeat (PPR) proteins found in mammalian 
mitochondria [90].  
The PPR proteins were first discovered in plants [91] and are characterized by several PPR 
repeats of around 35 amino acids each. They constitute a large family of proteins that mostly 
localize to organelles such as mitochondria and chloroplasts, exhibiting RNA binding 
properties and involvement in RNA metabolism [92-98]. Although MRPP3 is a PPR protein, 
it requires its binding partners MRPP1/2 complex to present the pre-tRNA substrate for 5´-
processing [99].  
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Figure 7: MRPP1, MRPP2 and MRPP3 constituting the human mt-RNase P localizes to mitochondria. The 
MRPP1/2 complex is responsible for methylation of human mt-tRNAs while the full MRPP1/2/3 complex 
performs 5´-processing of human mt-tRNAs. MRPP2 performs several other functions unrelated to tRNA 
processing. 
 
During the purification of mt-RNase P, the interaction of MRPP3 with the MRPP1/2 sub-
complex was observed to be very weak [60] suggesting that human mt-RNase P does not 
exist as MRPP1/2/3 complex, but rather as an intermediate transient complex. The C-terminal 
domain of MRPP3 also harbors conserved sequence blocks displaying four conserved amino 
acids initially speculated to perform metal-ion co-ordination to perform catalysis like a 
metallonuclease protein [100]. The crystal structure of Arabidopsis thaliana PRORP1 [62] 
served as a reference to speculate on the global architecture and mode of substrate catalysis of 
MRPP3. However, unlike MRPP3, PRORP1 can perform 5´-tRNA cleavage on its own using 
metal ions like Mg2+/Mn2+ [62, 63].   
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2.2 Human mitochondrial RNase Z 
2.2.1 Background 
The 3´-processing of tRNAs is performed by RNase Z that acts on 5´-processed substrates 
[99, 101, 102]. These enzymes either exist as RNase Z-S (short form) found in all kingdoms 
of life or as RNase Z-L (long form) found exclusively in eukaryotes [103]. The nuclear 
genome in humans encodes both forms of RNase Z called ELAC1 and ELAC2 [104]. The 
short form ELAC1 localizes predominantly to the cytosol and also to the nucleus while the 
long form ELAC2 localizes to both the nucleus and mitochondria [65, 104-109]. 
 
2.2.2 ELAC2 
ELAC2 processes 3´-trailer sequences in vitro [110] and its silencing causes accumulation of 
unprocessed precursor transcripts [65, 101]. Thus, ELAC2 plays a major role in proper 
mitochondrial function [111]. Noteworthy, in some cases, ELAC2 is not involved in the 3´-
processing such as in case of the mt-tRNA genes of tRNATyr and tRNACys that overlap by 1 
nucleotide [15]. The generation of 3´-processed end of tRNATyr is a result of addition of an 
adenosine by mitochondrial poly(A) polymerase (mtPAP) after the RNase P cleavage of 
downstream tRNACys [112]. It was reported that a protein called PPR containing domain 1 
(PTCD1) associates with ELAC2 [65]. The PTCD1 protein is characterized to negatively 
influence the levels of leucine tRNAs in mitochondria [113, 114]. So far, the precise interplay 
of ELAC2 with PTCD1 remains to be established. Either PTCD1 works in association with 
ELAC2 or as alternate 3´-processing machinery during the lack of ELAC2. 
 
2.3 CCA addition 
The maturation of mt-tRNAs is achieved by the addition of cytosine-cytosine-adenine (CCA) 
to the 3´-end of 5´,3´-processed precursors and is performed by nucleotidyl transferases 
[115]. In human mitochondria, transfer RNA nucleotidyl transferase 1 (TRNT1), alternatively 
called as CCA-adding enzyme (CCA-E) is responsible for 3´-CCA addition, a pre-requisite 
for codon-specific amino acid attachment via aminoacylation [116]. TRNT1 performs just a 
single round of CCA addition due to its compact binding pocket. While doing so, TRNT1 
interacts only with the sugar-phosphate backbone and not the nucleic acid template [117-
120]. The tRNAs then undergo specific modifications at specific sites to attain proper folding, 
that are then recognized by the corresponding aminoacyl tRNA synthetases [109, 121].  
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2.4 tRNA modifications 
The post-transcriptional modifications on various classes of RNA are carried out by a 
multitude of proteins. So far, around 130 different RNA modifications are reported, wherein 
tRNAs are the major targets of most common modifications such as methylation [122, 123]. 
The tRNA modifications are shown to be essential for stabilizing the tRNA teritiary structure, 
promote interaction with certain key enzymes, aminoacylation and accurate codon-anticodon 
decoding for an efficient translation [67, 68, 124-129]. Several tRNA-modifying enzymes are 
involved in mt-tRNA modifications, the lack of which leads to tRNA degradation [130] and 
cause several diseases [131]. The mammalian mt-tRNAs generally lacks a canonical D/T 
loop interaction, displaying an overall low melting temperature and hence is heavily reliant 
upon such modifications for stability and functional purposes [66, 128, 132, 133]. In 
mammalian mitochondria, more than 100 mt-tRNA post-transcriptional modifications are 
reported [66]. Several databases such as MODOMICS [134] and the RNA modification 
database [135] are dedicated towards careful documentation of reported modifications in 
bacteria, archaea and eukarya. 
 
2.5 Aminoacylation 
The aminoacylation of tRNAs is a process in which the mature tRNAs with a specific 
anticodon are charged with corresponding amino acids in two distinct steps, brought about by 
several aminoacyl-tRNA synthetases (aaRSs) [136]. The aminoacylation of 22 mt-tRNAs is 
carried out by 19 nuclear-encoded aaRSs targeted to mitochondria [26, 137]. Except the cases 
of mt lysine aaRS and mt glycine aaRS that share the same gene as their cytoplasmic 
counterparts, all 17 other aaRS machinery have distinct nuclear genes of their own [128]. 
Noteworthy, a single mt serine aaRS aminoacylates both the mt-tRNASer(AGY) and mt-
tRNASer(UCN); and a single mt leucine aaRS aminoacylates both the mt-tRNALeu(CUN) and mt-
tRNALeu(UUR) [138]. As the mammalian mitochondria lacks glutamine aaRS, the 
aminoacylation of mt-tRNAGln deviates from the standard pathway wherein the synthesis of 
Gln-tRNAGln occurs by misacylation to Glu-tRNAGln followed by transamidation to Gln-
tRNAGln [139].  
The aaRS display a high degree of specificity towards their cognate tRNAs by recognizing 
key identity elements such as the anticodon triplet, the N1-N72 base pair in the acceptor stem 
and the discriminator base [136]. However, the mt-aaRSs differ from its cytoplasmic and 
bacterial counterparts in that it displays a more relaxed tRNA discrimination [140]. A wide 
range of human diseases are linked to mutations in mt-aaRSs [141, 142] including 
mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) and 
myoclonic epilepsy with ragged red fibers (MERRF) among many. The proper 
aminoacylation of mt-tRNAs is henceforth crucial for normal translation of 13 polypeptides 
required for OXPHOS. 
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3 HUMAN MITOCHONDRIAL DISEASES 
 
The human mt diseases are caused either due to mutations in the nDNA, whose gene products 
play vital roles inside mitochondria or due to mutations in the mtDNA primarily affecting 
OXPHOS [12, 143]. A variety of such mt diseases displaying biochemical, genetic and 
clinical heterogeneity have been reported [12, 143] since the first clinical study was published 
in 1959 [144]. The databases such as MITOMAP [145] and MAMIT (Mammalian 
mitochondrial tRNA) database [146] serve as useful platforms with a compilation of all 
human pathologies originating due to mitochondria-associated mutations. Several strategies 
and therapies to address human mt diseases are currently under developmental stage [143, 
147]. 
 
3.1 Significance, prevalence and occurrence 
The heterogenous set of human mt diseases can occur at any stage of life and affects multiple 
organs including brain, heart and liver, all of which consume high amounts of energy [12, 
148]. The onset of clinical symptoms is observed when the patient cells carry multiple copies 
of mutant mtDNA above a critical threshold in relation to the wild-type (referred to as 
heteroplasmy), when the disease phenotype becomes more apparent. Although the exact 
percentage of such mutant mtDNA causing disease phenotype varies, 70% or more is 
generally considered to be a critical threshold [149]. Noteworthy, even 25% mutant mtDNA 
or less was shown to cause disease [150, 151].    
The population-based studies done in Sweden [152] and Australia [153] indicated that about 
1 in 20,000 children are affected by such mt-diseases, prevalent also in adults [154].  A recent 
study found that about 1 in 5000 individuals were affected by mtDNA mutations and reported 
prevalence over time [155, 156]. Thus, these reports highlight an urgent need to develop 
strategies to tackle them.  
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3.2 Mutations in mtDNA and nuclear encoded genes  
Early works indicated that specific mutations in mtDNA cause debilitating mt disorders [157, 
158]. These mutations may have been acquired via natural maternal inheritance [159] or may 
have been sporadically introduced. The defective maintenance machinery of mtDNA may 
also lead to introduction of disease-causing mutations as a consequence of nDNA mutations 
[160]. An estimated 15% of all mt disorders are caused due to mtDNA defects [154]. Most of 
the disease-causing mtDNA mutations are localized within the 22 mt-tRNA genes [161] 
causing more than 130 human disorders ranging in severity from mild weakness to life-
threatening cardiomyopathies [162, 163]. A compilation of all reported human pathologies as 
a result of mutations in the mt-tRNA genes is given in Table 3. 
The mitochondrial disorders may also originate due to mutations in the nDNA [154] whose 
gene products are responsible for maintaining proper mt function by playing specific roles in 
processes such as mt transcription, processing of RNA species towards maturation and mt 
translation [26]. The clinical manifestations of such mutations range from biochemical 
defects to severe neurological disorders. The mutations in the key mt-tRNA processing 
enzymes such as MRPP1, MRPP2, MRPP3, ELAC2 and TRNT1 are implicated in several 
diseases and are compiled in Table 4. 
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mt-tRNA Mutations in mtDNA Pathology caused 
Phe T582C, G583A, A608G, G611A, T618C, G622A EI, MELAS, MERRF, MM, TNS 
I, MELAS, MERRF, MM, TNS Val G1606A, G1642A, G1644T, T1659C AMDF, EI, H, LS, ELAS 
Leu(UUR)  G3242A, A3243G, A3243T, G3249A, T3250C, A3251G, A3252G, 
C3254G, G3255A, C3256T, T3258C, A3260G, T3264C, T3271C, 
delT3272, T3273C, C3275A, A3280G, G3283A, A3288G, T3291C, 
A3302G, C3303T 
D, DM, DMDF, EI, G, IH, KS, LA, 
MELAS, MERRF, MERRF-like 
MELAS, MM, MMC, MTMD, PEM 
Ile A4267G, A4269G, T4274C, G4284A, T4285C, T4290C, T4291C, 
A4295G, G4298A, A4300G, G4309A, A4317G, C4320T 
AMDF, CPEO, DM, ECM, EM, 
FICP, HCM, HHH, MICM, MM, 
PEO, SNHL 
Met T4409C, A4435G, G4450A LHON, MM 
Trp G5521A, G5532A, InsT5537, G5540A, G5549A CD, D, DEMCHO, LS, MILS, MM, 
NGI, PEM 
Asp A7256G MM 
Lys A8296G, T8300C, A8308G, G8313A, T8316C, A8326G, G8328A, 
G8342A, A8344G, A8347G, T8355C, T8356C, G8361A, T8362G, 
G8363A 
AR, C, DEAF, DMDF, EI, EM, 
HCM, LS, MELAS, MERRF, 
MICM, MNGIE, MS, PEO, SM 
Gly T9997C, A10006G, T10010C, A10044G CIPO, EM, MHCM 
Arg A10438G EM 
His G12147A, G12183A, G12192A CM, MELAS, MERRF, PR, SNHL 
Ser(AGY)  C12246A, G12207A, C12258A CIPO, DMDF, EM, MM 
Leu(CUN)  G12294A, T12297C, A12299C, G12301A, A12308G, T12311C, 
G12315A, A12320G, G12334A 
AISA, CPEO, DCM, EI, MELAS, 
MERRF, MM  
Thr    G15915A, A15923G, A15924G, delT15940, G15950A, A15951G ADPD, LHON, LIMM, MM 
Pro     T15965C, G15990A, C15995T ADPD, C, MM, O 
Glu     T14687C, T14693C, T14696C, A14709G, C14724T, C14739T D, EI, EM, L, LA, MELAS, MM, 
PR, PRF 
Ser(UCN) InsG7472, A7480G, C7497T, A7510G, A7511G, A7512G AMDF, DEAF, LA, MERRF-like, 
MM, PEM, RRF, SNHL 
Tyr    T5843C, A5874G, G5877A, delT5885 CD, CPEO, EI, LW, MM 
Cys   C5783T, A5814G, C5780T DEAF, DCM, EM, MELAS, MM, 
PEO, SNHL 
Asn  C5703T, A5692G, A5728G, A5693G, C5698T CPEO, lethal MM, MM, MOF, PEO 
Ala   C5591T, A5628G, C5650T CEPO, MERRF, MM 
Gln   C4332T, A4336G, InsT4370, T4381C ADPD, CD, D, EM, LHON, MM 
 
Table 3: A compilation of mtDNA mutations implicated in mt diseases compiled from MAMIT database [146]. 
The abbreviations are listed in the glossary in section 10. 
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Protein #amino acids 
(including 
MTS) 
Functions Reported 
mutations  
Pathological implications References 
MRPP1 403 m1A9/m1G9 methylation, 
5´-tRNA cleavage (mt-
RNase P) 
R181L, T272A  Combined oxidative 
phosphorylation defect type 
30 
[69, 164] 
MRPP2 261 m1A9/m1G9 methylation, 
5´-tRNA cleavage (mt-
RNase P), isoleucine 
degradation, metabolism 
of fatty acids,  sex 
hormones and 
neuroactive steroids 
V12L, V65A,  
D86G, L122V, 
R130C, Q165H, 
A154T, A157V, 
A158V, V176M, 
P210S, K212E, 
R226Q, N247A, 
E249Q 
HSD10 disease (MHBD 
deficiency), colorectal 
cancer, alzheimer’s disease, 
choreoathetosis, refractory 
epilepsy and learning 
disability, intractable 
epilepsy and global 
developmental delay 
[69, 83, 85, 
165-181] 
MRPP3 583 5´-tRNA cleavage (mt-
RNase P), possible 
modulation of rate of 
post-transcriptional 
modification 
N437S, A485V Perrault syndrome  [182, 183] 
ELAC2 826 3´-tRNA cleavage (mt-
RNase Z) 
F154L, R211Q, 
S217L, L423F, 
G487R, T520I, 
A541T, E622V, 
R781H, G806R 
Prostate cancer hereditary 2, 
combined oxidative 
phosphorylation deficiency, 
infantile hypertrophic 
cardiomyopathy and 
complex I deficiency, 
intellectual disability 
[104, 111, 
184, 185] 
TRNT1 434 3´-CCA addition  T154I, M158V, 
L166S, R190I, 
I223T, I326T, 
K416E 
Sideroblastic anemia with 
B-cell immunodeficiency, 
periodic fevers and 
developmental delays; 
retinitis pigmentosa with 
erythrocytic microcytosis 
[186-190] 
 
Table 4: A list of reported mutations in the key nuclear-encoded genes and the diseases they cause are compiled 
from MalaCards database [191]. MTS: mitochondrial target sequence. 
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4 METHODOLOGY 
 
The research studies towards the structural and biochemical characterization of biomolecular 
complexes require significant quantities of pure proteins and tRNAs that were produced as 
shown below (Figure 8). The human mt-proteins were produced by the application of 
recombinant DNA technology [192-194], wherein they are expressed in E. coli bacterial cells 
and purified using advanced chromatographic techniques described below. The human mt-
tRNAs were synthesized by in vitro transcription using T7 RNA polymerase and purified by 
a combination of glm-S based affinity purification setup [195] and chromatography.    
 
 
 
Figure 8: A flowchart showing the pipeline for generation of pure mt-proteins and mt-tRNAs. These 
biomolecular components will then be used for downstream studies.   
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4.1 Recombinant production of mt-proteins 
The genes encoding human mitochondrial protein subunits are cloned into plasmids such as 
pNIC28-Bsa4 expression vector using standard molecular biology tools. The new 
recombinant plasmid is then transformed into E. coli bacterial cells of a particular strain such 
as E. coli BL21 (DE3), that consists of a re-engineered chromosomal setup, wherein the 
expression of encoded T7 RNA polymerase gene is controlled by a modified lac operon 
system. A lac repressor normally remains bound to this lac operon, blocking the expression of 
T7 RNA polymerase gene by E. coli RNA polymerase. The induction of cells by isopropyl β–
D-1-thiogalactopyranoside (IPTG) causes the lac repressor to be released, resulting in the 
transcription of the T7 RNA polymerase gene by E. coli RNA polymerase (Figure 9). Thus, 
the newly synthesized T7 RNA polymerase binds to the T7 promoter region of plasmid DNA 
harboring the desired gene to produce the protein of interest [192].   
 
 
 
Figure 9: A scheme of recombinant expression of proteins in bacterial cells. The protein expression is induced 
when the bacterial cells are provided with rhamnose and IPTG. 
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4.2 Purification of mt-proteins 
The bacterial cells harboring the recombinant protein are lysed using homogenization or 
sonication and the cell lysate is subjected to centrifugation to separate the soluble fraction 
from undesired cell debris. The soluble fraction is then subjected to step-by-step purifications 
(Figure 10) starting with capture of desired macromolecule by methods such as immobilized 
metal-affinity chromatography (IMAC), followed by intermediate purification steps such as 
ion-exchange chromatography (IEC) and heparin affinity chromatography and a final 
polishing step by size-exclusion chromatography (SEC).  
 
 
 
Figure 10: The pipeline for extraction and purification of proteins, recombinantly expressed in bacterial cells. 
The degree of purity is the highest in the final step of purification.  
 
The recombinant proteins are generally expressed in fusion with affinity tags such as His-tag, 
consisting of six histidine (His)6 residues [196]. The amino acids histidine and cysteine have 
a strong affinity to metal ions such as nickel or zinc at neutral pH [197]. In IMAC, hexa-
histidine tagged recombinant proteins are captured from a pool of bacterial proteins by 
immobilizing them on a metal-chelate resin and washing off the huge amounts of undesired 
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polysaccharides employs a combined use of its negative charge and affinity properties to 
separate biological macromolecules [198]. IEC exploits the charge property of the target 
protein, wherein the protein is passed through a resin consisting of oppositely charged 
moieties. The efficient separation is achieved by differences in the degree of interaction of 
different molecules to the matrix of a particular charge [199]. As a final polishing step, SEC 
(also called gel filtration) offers a robust technique to obtain homogenous mixture of pure 
proteins, protein-protein or protein-nucleic acid complexes. The separation is based on the 
differences in migration pattern of molecules of varying sizes and shapes through medium of 
spherical particles [200].   
 
4.3 In vitro synthesis of mt-tRNAs 
The in vitro synthesis of human mt-tRNAs that we have used is based on the optimization of 
a protocol described for native affinity purification of RNA [195]. The design of a typical 
template for the transcription of tRNAs is as follows. It starts with a T7 promoter sequence 
immediately after a short T7 landing region, followed by the DNA sequence of choice, glm-S 
ribozyme gene sequence and MS2 coat protein sequence (Figure 11).  
The first strategy employed here is to transcribe the template in the above-described set-up 
using T7 RNA polymerase and immobilize the transcription product onto a nickel-affinity 
resin using a hexahistidine-tagged form of the MBP-MS2 coat fusion protein (HMM) that 
binds to the MS2 coat protein-binding stem-loops at the 3´-end of transcription product 
(Figure 11). The addition of glucosamine-6-phosphate (GlcN6P) activates the glm-S 
ribozyme, releasing the desired tRNA in the flowthrough and washes [201, 202]. 
An alternate strategy of tRNA production by co-transcriptional glm-S cleavage was also 
used, wherein the GlcN6P is already provided during the in vitro transcription to facilitate 
cleavage already during the reaction. The transcription product containing a mixture of 
cleaved and uncleaved RNA species are then separated using ion-exchange chromatography 
(Figure 11). The use of chromatography can also be extended towards a traditional run-off 
transcription that will then normally give a heterogenous 3´-end.  
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Figure 11: The pipeline for generation of pure mt-tRNAs. A: HMM-based tRNA production B: Co-
transcriptional glm-S cleavage based tRNA production.    
 
4.4 Crystallization of biological molecules and bio-molecular complexes 
One of the strategies employed in the structure determination of proteins, nucleic acids and 
protein-nucleic acid complexes is by crystallizing them and collecting their X-ray diffraction 
data at high resolution. Such crystallization is achieved by subjecting the pure, homogenous 
macromolecular species to a supersaturated state using a suitable precipitating agent to allow 
nucleation and crystal growth [203, 204]. The successful crystallization depends on several 
factors such as purity and concentration of the macromolecule, temperature and composition 
of the precipitant solution. A wide range of commercial kits is available for initial 
crystallization screening. 
The initial crystals obtained from the sparse matrix screenings are generally of poor-quality 
and hence the crystal conditions have to be optimized to obtain better quality crystals to 
collect the best X-ray diffraction data. The optimization of crystallization conditions involve 
systematic, incremental changes in various parameters such as pH, concentration of 
precipitant, concentration of macromolecule, presence of additives and temperature [205]. 
The quality of crystals can also be improved by strategies like seeding, wherein a crystalline 
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material is introduced into a crystallization drop as a ‘seed’ to promote crystal growth or by 
crystal dehydration or by several other post-crystallization methods such as soaking [206-
209]. Thus, the successful structure determination by X-ray crystallography is based upon the 
generation of the best crystals of the macromolecular species, produced by the above-
described methods. 
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5 SUMMARY OF PAPERS 
 
5.1 PAPER I 
Structure of the nuclease subunit of human mitochondrial RNase P 
This paper describes the crystal structure of MRPP3 at high resolution and provides a 
comprehensive explanation as to why it needs MRPP1/2 and pre-tRNA substrate for 5´-
processing.  
The human mt-RNase P required an additional protein component from the mitochondrial 
extract along with MRPP1 and MRPP2 for 5´-processing of pre-tRNAs. This protein was 
identified to be the product of KIAA0391 gene expression and was named as MRPP3 [60]. 
The C-terminal domain of MRPP3 sequence showed conserved blocks and was suggested to 
co-ordinate metal ions to act as a protein metallonuclease [100]. In plant mitochondria and 
plastids, just one protein component PRORP1 was shown to perform 5´-processing of 
precursor tRNAs [63]. We designed the study to investigate the structural data of the human 
MRPP3 protein to understand as to why it is unable to function on its own.  
To perform the study, we required MRPP3 (Uniprot: O15091; residues 45-583) along with 
the other two human mt-RNase P subunits: MRPP1 (Uniprot: Q7L0Y3; residues 40-403) and 
MRPP2 (Uniprot: Q99714; residues 1-261). A suitable pre-tRNA substrate was needed to 
evaluate the pre-tRNA 5´-processing activity. The in vitro transcribed pre-tRNA tyrosine 
substrate with suitable 5´- and 3´-extensions was produced by using a combination of glm-S 
based affinity purification setup [195] and chromatography purification. As MRPP1 and 
MRPP2 were reported to form a strong protein-protein complex [60, 64], we cloned them into 
a single pNIC-CTHF vector (Figure 12) such that untagged MRPP2 precedes C-terminally 
His-tagged, Flag-tagged MRPP1 separated by a ribosome re-initiation spacer.  
The MRPP3 protein was cloned into pNIC28-Bsa4 vector (Figure 12), subjected to 
recombinant expression in E.coli KRX cells and purified using Ni-IMAC (Nickel-IMAC) and 
SEC. The full-length protein (45-583) lacking MTS was subjected to crystallization trials. 
However, no crystal hits were obtained. Hence, we created several N-terminal truncated 
variants of MRPP3 lacking one or more PPRs. Each of the truncated variants were cloned 
into pNIC28-Bsa4 vector and confirmed by DNA sequencing. These variants were expressed 
and purified like the WT protein and were subjected to crystallization trials. One variant 
(residues 207-583) generated crystals. This crystallization condition was optimized and X-ray 
diffraction data was collected to determine the structure of the protein. 
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Figure 12: An illustration of constructs of human mt-RNase P subunits. A: MRPP1/2 subcomplex was produced 
using pNIC-CTHF-MRPP2-MRPP1 construct. B: An outlook of N-terminal re-engineered MRPP3 truncations 
created for crystallization. All variants were cloned into pNIC28-Bsa4 vector. 
 
The overall structure of MRPP3 resembled the structure of Arabidopsis thaliana PRORP1 
[62] containing three domains: N-terminal PPR domain, central domain and C-terminal 
metallonuclease domain. Yet, the structure of MRPP3 differed from PRORP1 both in terms 
of relative orientation of individual domains to each other and at molecular level. The active 
site of MRPP3 located in the metallonuclease domain lacked metal ions and showed severe 
distortion unlike PRORP1, whose active site coordinated two Mg2+/Mn2+ ions via four 
conserved aspartate residues.  
Initially, we suspected that perhaps the chelating crystallization condition may have caused 
the MRPP3 to loose Mg2+ ions causing the active site to be disorganized. Hence, we 
crystallized the MRPP3 protein in several non-chelating conditions including soaking the 
crystal in excess MgCl2 and solved the structure. Still, the overall architecture of the active 
site remained the same confirming that our structure was not an artifact. We then created 
MRPP3 active site mutants to evaluate if its activity is indeed coordinated by four aspartates 
D409, D478, D479 and D499. By performing pre-tRNA activity assays we confirmed that the 
suspected four aspartates are indeed critical for catalysis. By following the architecture of the 
PRORP1 active site, we then extended our mutational analysis to evaluate if the active site of 
MRPP3 could be rebuilt so as to make it loose the requirement of the MRPP1/2 complex for 
pre-tRNA catalysis. However, all attempts to render MRPP3 active by itself were 
unsuccessful. We speculate that in the presence of the MRPP1/2 sub-complex and the pre-
tRNA substrate, MRPP3 undergoes complex domain re-arrangements and re-organization of 
its active site to be able to perform the 5´-tRNA cleavage.  
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5.2 PAPER II 
The MRPP1/MRPP2 complex is a tRNA-maturation platform in human mitochondria 
This paper describes the previously unknown wider role of the human MRPP1/2 complex in 
the human mt-tRNA maturation pathway (Figure 13). The mt-tRNA processing and 
maturation is a systematic, ordered, step-by-step procedure starting with 5´-processing by mt-
RNase P, 3´-processing by mt-RNase Z followed by 3´-CCA addition and the post-
transcriptional modifications [26]. The MRPP1/2 complex along with MRPP3 constitutes the 
human mt-RNase P that performs 5´-tRNA processing [60, 61]. MRPP1 forms a strong 
protein complex with the multifunctional MRPP2 protein to perform methylation of mt-
tRNAs at position 9 [64, 69]. Noteworthy, this methylation function of the MRPP1/2 
complex is not a pre-requisite for RNase P activity [64]. The MRPP1/2 complex was thus by 
far only discussed in the context of mt-RNase P. 
Our unsuccessful attempts in rebuilding the active site of MRPP3 by performing specific 
mutations as published in PAPER I highlighted the then unknown significance of MRPP1/2 
sub-complex. During this work, we also observed that MRPP3 could perform multiple-
turnover reactions unlike MRPP1/2 complex that performed single-turnover reactions. The 
MRPP1/2 complex stays with the pre-tRNA substrate even after MRPP3-led 5´-cleavage is 
complete. This led us to question as to how does the 5´-processed tRNA undergo 3´-
processing by RNase Z while still remaining bound to MRPP1/2. The previous reports have 
shown that the ELAC2 protein functions as RNase Z in human mitochondria to perform the 
3´-processing of 5´-processed mt-tRNAs [210]. There were no studies that evaluated the link 
between 5´- and 3´-processing events, giving an impression that these events were 
independent and uncoupled. Noteworthy, one study reported that the depletion of MRPP1 
affected both 5´- and 3´-processing [101] without exploring this observation in detail. 
To investigate these phenomena more closely and to bring clarity to the mt-tRNA processing 
pathway, we performed several in vitro activity assays and analytical size-exclusion 
chromatography experiments. We show that MRPP1/2 is not only participating in 5´-
processing of mt-pre-tRNAs, but also hosts them in further steps. We show that ELAC2 led 
3´-cleavage of mt-tRNAs is able to occur while they remain bound to MRPP1/2. Moreover, 
we have closely evaluated both the physiological and non-physiological conditions and report 
that the 3´-processing by ELAC2 is significantly enhanced in 17 out of 22 mt-tRNAs in the 
presence of the MRPP1/2 complex.  
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Figure 13: An illustration depicting MRPP1/2 complex as a platform for maturation of mt-tRNAs hosting them 
through 5´-processing with MRPP3, 3´-processing with ELAC2 and 3´-CCA addition with CCA-E. The exact 
mechanism by which MRPP1/2 releases tRNA is so far unknown and requires the evaluation of tRNA 
modifying enzymes, aminoacyltransferases and perhaps even the components of mitoribosome in this regard. 
 
After the 3´-processing, MRPP1/2 continues to bind the 5´-, 3´-processed tRNA substrate and 
allows CCA-E to perform the 3´-CCA addition that is critical for aminoacylation of mature 
tRNAs [211]. Although CCA-E can perform the 3´-CCA addition on its own, it displays an 
error-prone behavior of addition of more nucleotides in non-physiological conditions. This 
behavior is completely abolished by the presence of the MRPP1/2 complex, wherein the 
proper functioning of CCA-E is extended across a broad range of physiological and non-
physiological conditions. Thus, the relevance of the MRPP1/2 sub-complex in downstream 
tRNA maturation processes are validated using a combination of in vitro activity assays and 
complexing studies between various molecular players. At what stage does the sub-complex 
releases the mature tRNA remains an open-ended question that requires further evaluation in 
the context of processes such as mt-tRNA modifications and aminoacylation.      
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5.3 PAPER III 
Clinically relevant mutations in the acceptor stem of mitochondrial tRNA(Lys) strongly 
affects RNase P activity 
Mitochondrial diseases constitute a major class of commonly occurring human diseases 
requiring both clinical and biochemical characterization [128, 212]. The molecular causes of 
such pathologies are either due to mutations in the nuclear genes important for mt-function or 
due to mutations in the mtDNA, or both, giving rise to mutant proteins or mutant mt-tRNAs 
causing functional defects. Many mutations are localized within mt-tRNA genes in the 
mtDNA, with over 200 such mutations implicated in various mitochondrial diseases (Figure 
14) [212].  
 
 
Figure 14: An illustration depicting the prevalence of reported pathological mutations at various locations of mt-
tRNAs (data compiled from MAMIT database). 
 
The 5´-tRNA cleavage by human mt-RNase P is the first step towards the release and 
maturation of individual RNA species from the polycistronic transcript. Atleast 28 mutations 
in the tRNA acceptor stem have been linked to various mitochondrial diseases such as 
MELAS and MERRF. We aimed to explore the consequences of mutations in the acceptor 
stem of the mt-tRNALys in terms of RNase P processivity. The choice of tRNA lysine for this 
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study was motivated by the high number of reported pathologies caused by mutations in its 
acceptor stem. 
We observed an overall reduced human mt-RNase P activity in mt-tRNALys harboring 
pathological mutations in its acceptor stem. This observation is crucial not just from disease 
perspective, but also highlights the role of an intact acceptor stem as an identity element for 
stable mt-RNase P binding and catalysis. Our quest to identify the molecular cause of reduced 
RNase P processivity indicated that the nuclease activity of MRPP3 is affected, while the 
MRPP1/2 sub-complex can stably form a complex with the mt-tRNALys irrespective of the 
presence or absence of the mutation. It remains to be established if the reduced 5´-
processivity is because MRPP3 is unable to form a complex with MRPP1/2-pre-tRNA or 
because it’s active site reorganization is affected.  
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6 FUTURE PERSPECTIVES 
 
This thesis summarizes the findings on the processing of human mt-tRNAs, crucial in health 
and diseases adding significant knowledge to the field of PRORP’s.  
In PAPER I, we have solved the crystal structure of MRPP3 showing a peculiarly distorted 
active site. We suggest that the activity of human mt-RNase P requires complex 
reorganization of active site of MRPP3 brought about by MRPP1/2 bound to pre-tRNA 
substrate. The understanding of the precise mechanism by which such a reorganization would 
occur requires the structural elucidation of human mt-RNase P – tRNA complex.  
In PAPER II, we have unraveled the wider role of MRPP1/2 complex in tRNA maturation 
pathway. The obvious next step would be to investigate the mechanism of release of mature 
tRNA from MRPP1/2 sub-complex. In this regard, the role of tRNA modifying enzymes and 
aminoacyltransferases must be closely inspected. Perhaps like with MRPP3, ELAC2 and 
CCA-E, MRPP1/2 might allow tRNA modifying enzymes and aminoacytransferases to 
perform their function while being bound to the tRNA substrate.  
The tRNAVal gene is present in between the genes encoding 12S and 16S rRNAs in the 
human mtDNA. The human mitoribosome structure revealed that tRNAVal is an integral 
component of mitochondrial large subunit (mtLSU) [34]. The maturation of pre-tRNAVal 
follows standard RNase P and RNase Z processing [213]. In this regard, it is noteworthy that 
in PAPER II, we observed strong enhancement in 3´-processing of tRNAVal by MRPP1/2-
ELAC2 in relation to ELAC2 alone. It remains to be established as to how the MRPP1/2 
mediated processing of mt-tRNAVal is co-ordinated with the mitoribosome biogenesis. Such a 
study would help us decipher the links between mtDNA mutations in tRNAVal gene and 
implicated pathologies [214-218] perhaps resulting due to improper mitoribosome assembly. 
The methylation of mt-tRNAs brought about by MRPP1/2 complex was shown to not be a 
pre-requisite for RNase P activity [64]. Given the recent knowledge of MRPP1/2 as a tRNA-
maturation platform [99], one could evaluate if the presence or absence of methylation of mt-
tRNAs would have an effect on downstream processing mechanisms.  
In PAPER II, we observed that the tRNALeu(UUR) and tRNALeu(CUN) showed a moderate to no 
significant difference in MRPP1/2-led enhancement of ELAC2 processing. The ELAC2 
protein was shown to associate with PTCD1 [65] that negatively regulates leucine tRNAs 
(both tRNALeu(UUR) and tRNALeu(CUN))[113]. In this regard, the 3´-processing mechanism of 
leucine tRNAs in mitochondria must be closely inspected to evaluate if PTCD1 may act in 
association with ELAC2 or as an alternate to ELAC2 as speculated [65]. This evaluation 
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would thus require a careful and intense investigation of interplay between MRPP1/2 
subcomplex, ELAC2, PTCD1 and mt-leucine tRNAs. 
The mtDNA mutations cause several life-threatening mitochondrial diseases and have severe 
impact on human health due to the lack of effective treatments. Several procedures are being 
developed to alleviate the effects of mutant mtDNA expression by employing strategies such 
as the expression of mt genes in the nucleus and the transfer of healthy mitochondria between 
cells [219]. Moreover, certain mutations in the nuclear encoded mt-RNase P proteins can 
cause processing defects leading to accumulation of precursor transcripts. The careful 
biochemical and structural characterization of biomolecules participating in cellular and 
organellar metabolic pathways are crucial for the development of such novel strategies.  
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7 POPULAR SCIENCE SUMMARY 
 
Our body is made up of billions of cells and each cell has a nucleus (like a city council) and 
many small factories called ‘mitochondria’ where energy is produced. Each of these factories 
employs 22 tRNAs and several proteins (biological classes of molecules) to ultimately 
produce energy. It is a complex phenomena and involves multiple biological reactions. One 
such set of reactions involves the preparation of tRNAs by certain proteins whose journey 
starts from the nucleus.  
These proteins prepare/process the tRNAs inside the mitochondria in 3 major steps (Figure 
15) involving proteins like MRPP1, MRPP2, MRPP3, ELAC2 and CCA-E. In the first step, 
the proteins MRPP1 and MRPP2 (MRPP1/2) hold the tRNA and MRPP3 performs the first 
cut. Then, another protein called ELAC2 performs the second cut while MRPP1/2 continues 
to hold onto tRNA. In the third step, a special extension is added by another protein called 
CCA-E, this while MRPP1/2 is still present with the tRNA. After these three steps, other 
proteins act on the tRNA to make it ready to participate in other pathways towards energy 
production. We still do not know at what stage the tRNA leaves the MRPP1/2.  
 
Figure 15: The major steps of tRNA processing explained using simple analogy. Step 1 refers to 5´-processing 
by MRPP1/2/3, step 2 refers to 3´-processing by MRPP1/2/ELAC2 and step 3 refers to 3´-CCA addition by 
MRPP1/2/CCA-E.   
 
Sometimes, when there are problems in tRNAs or proteins, they cannot perform these 
activities and this can cause human diseases. We have explored how the problems in tRNAs 
can affect the first step. Thus, this thesis has contributed to our knowledge of the grooming 
processes of tRNAs in human mitochondria.  
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10 GLOSSARY 
The following abbreviations were compiled from the MAMIT database [146]. 
ADPD (Alzheimer’s Disease and Parkinson Disease) 
AISA (Acquired Idiopathic Sideroblastic Anemia) 
AMDF (Ataxia, Mental deterioration, DeaFness) 
AR (Axenfeld-Rieger anomaly) 
CD (Cox Deficiency) 
CIPO (Chronic Intestinal PseudoObstruction with myopathy) 
CPEO (Chronic Progressive External Opthalmoplegia) 
D (Diabete) 
DCM (Dilated CardioMyopathy) 
DEAF (Maternally inherited DEAFness/Aminoglycoside-induced DEAFness) 
DEMCHO (DEMentia, CHOrea) 
DM (Diabetes Mellitus) 
DMDF (Diabetes Mellitus, DeaFness) 
ECM (EncephaloCardioMyopathy) 
EI (Exercise Intolerance) 
EM (EncephaloMyopathy) 
FICP (Fatal Infantile Cardiomyopathy Plus a MELAS-associated cardiomyopathy) 
H (Hemiplegia) 
HCM (Hypertrophic CardioMyopathy) 
HHH (Hypertension, Hypercholesterolemia, Hypomagnesemia) 
IH (Ineffective Hematopoiesis) 
KS (Kearns-Sayre syndrome) 
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L (Leukoencephalopathy) 
LA (Lactic Acidose) 
LHON (Leber Hereditary Optic Neuropathy) 
LIMM (Lethal Infantile Mitochondrial Myopathy) 
LS (Leigh Syndrome) 
LW (Limb Weakness) 
MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes) 
MERRF (Myoclonic Epilepsy with Ragged Red Fibers) 
MHCM (Maternally inherited Hypertrophic CardioMyopathy) 
MICM (Maternally Inherited CardioMyopathy) 
MILS (Maternally Inherited Leigh Syndrome) 
MM (Mitochondrial Myopathy) 
MMC (Maternal Myopathy and Cardiomyopathy) 
MNGIE (Mitochondrial NeuroGastroIntestinal Encephalomyopathy) 
MOF (MultiOrgan Failure) 
MS (Myoclonic Seizures) 
MTMD (Multiple Tumor in Mitochondrial Diabetes) 
NGI (NeuroGastroIntestinal syndrome) 
O (Opthalmoplegia) 
PEM (Progressive EncephaloMyopathy) 
PEO (Progressive External Opthalmoplegia) 
PR (Pigmentary Rentinopathy) 
PRF (Progressive Respiratory Failure) 
RRF (Ragged Red Fibers) 
SM (Skeletal Myopathy) 
SNHL (SensoriNeural Hearing Loss) 
TNS (Tubulointersitial Nephritis and Stroke) 
